Wellington, HBM lead €22m round for Adrenomed

The company plans to use the fresh capital to advance its lead drug candidate, Adrecizumab.

The round saw CEO Jens Schneider-Mergener step down from his position. The company said in a statement that it has identified a new candidate for the role and will announce this shortly.

Previous funding
Wellington Partners and HBM led a €24m series-D round for Adrenomed in November 2019, with Wellington deploying equity via Wellington Partners Life Sciences Fund V.

Company
Adrenomed develops therapeutic antibodies to preserve vascular integrity in critically ill patients, treating vascular leakage, congestion and septic shock. The company was founded in 2009 by the founders of Brahms, which was sold to Thermo Fisher that year for €330m. The company is based in Hennigsdorf and has fewer than 50 employees, according to LinkedIn.

People
Adrenomed – Andreas Bergmann (chief scientific officer); Bernd Wegener (chairman of the supervisory board).
Wellington Partners – Rainer Strohmenger (managing partner).
HBM Healthcare Investments – Priyanka Belawat (investment adviser).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Venture
• Germany
• Wellington Partners